Pfizer is a research-based biopharmaceutical global company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer's diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical includes the primary care, specialty care, established products, emerging markets and oncology customer-focused units. Diversified includes animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. The Company's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol), Lyrica (pregabalin, for neuropathic pain/fibromyalgia), Diflucan (fluconazole, an oral antifungal medication), Zithromax (azithromycin, an antibiotic), Viagra (sildenafil, for erectile dysfunction) and Celebrex/Celebra (celecoxib, an anti-inflammatory drug).

Company Growth (employees)
New York, US
Size (employees)
96,500 (est)
Pfizer was founded in 1848 and is headquartered in New York, US

Key People/Management at Pfizer

Ian Read

Ian Read

Chairman of the Board and Chief Executive Officer
Rady Johnson

Rady Johnson

Executive Vice President, Chief Compliance and Risk Officer
Doug Lankler

Doug Lankler

Executive Vice President, General Counsel
Albert Bourla

Albert Bourla

Chief Operating Officer, Pfizer
Frank D'Amelio

Frank D'Amelio

Executive Vice President, Business Operations and Chief Financial Officer
Chuck Hill

Chuck Hill

Executive Vice President, Worldwide Human Resources
Angela Hwang

Angela Hwang

Group President, Pfizer Essential Health
Freda Lewis-Hall

Freda Lewis-Hall

Executive Vice President and Chief Medical Officer
Kirsten Lund-Jurgensen

Kirsten Lund-Jurgensen

Executive Vice President and President, Pfizer Global Supply (PGS
Rod MacKenzie

Rod MacKenzie

Executive Vice President, Chief Development Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research and Development and Executive Vice President of Pfizer Inc
Laurie Olson

Laurie Olson

Executive Vice President, Strategy & Commercial Operations

Pfizer Office Locations

Pfizer has offices in New York, Buenos Aires, Bentley, Shanghai and in 37 other locations
New York, US (HQ)
235 East 42nd Street
Show all (42)

Pfizer Financials and Metrics

Pfizer Financials

Pfizer's revenue was reported to be $52.8 b in FY, 2016

Revenue (Q2, 2017)

12.9 b

Market capitalization (16-Feb-2018)

219 b
Pfizer's current market capitalization is $219 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


51.6 b49.6 b48.9 b52.8 b

Revenue growth, %


Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017


12.6 b11.4 b12.8 b12.4 b10.9 b11.9 b12.1 b12.9 b

Cost of goods sold

2.3 b2 b2.5 b2.4 b1.8 b

Gross profit

10.4 b9.3 b10.3 b10 b9 b

Gross profit Margin, %

USDY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016


3.2 b10.1 b2.2 b3.3 b3.6 b


6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b


12.4 b11.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017


2.1 b2.9 b3.4 b2.4 b3.6 b3.7 b3.1 b


6.5 b6.1 b6.2 b6.4 b5.8 b5.8 b7.6 b7.6 b

Current Assets

59.5 b57.8 b58.3 b57 b49.4 b51.7 b45 b38.5 b41.3 b43.8 b35.9 b36.4 b


12.4 b12.3 b12.2 b12 b11.5 b11.4 b13.7 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b

Accounts Receivable

940 m148 m21 m(134 m)


(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b

Depreciation and Amortization

3.1 b

Cash From Operating Activities

4.8 b

Purchases of PP&E

(806 m)
USDY, 2017


133.6 k

Financial Leverage

2.9 x
Show all financial metrics

Pfizer Operating Metrics

Y, 2014Y, 2015Y, 2016

Active Clinical Studies


Phase III Trials


Discovery Projects


Drugs Approved by FDA

Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
MedivationAugust 22, 2016$14 b
Anacor PharmaceuticalsJune 24, 2016$5.2 b
AllerganNovember 23, 2015$160 b

Pfizer Market Value History

Pfizer Revenue Breakdown

Pfizer Median Salaries

Source: 241 public H-1B filings from Pfizer

Pfizer's Web-traffic and Trends

Pfizer Online and Social Media Presence

Pfizer News and Updates

Former Teva generics chief Olafsson steps into CEO seat at growth-challenged Hikma

Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals. The company trumpeted the appointment Tuesday, noting that current CEO Said Darwazah would slide over into the executive chairman’s spot.

Pfizer's Bavencio flops third key study, this time in lung cancer. Can crossover really explain it?

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.

FDA Form 483 shows Pfizer repeating same mistakes at troubled fill-finish plant

Pfizer said several weeks ago that the FDA had updated the status of its troubled Kansas fill-finish plant, paving the way for drug approvals, and sure enough this week Novartis announced an FDA nod for its Copaxone generic being produced there. But a recently released document from the last inspect…

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Despite competitors' efforts to pick up market share, an analyst figures J&J's Remicade will dominate the market again in 2018.

Global Endometrial Cancer Treatments Market 2018 Segmentation, Demand, Growth, Trend, Opportunity and Forecast to 2023

Endometrial Cancer Treatments Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Bile Duct Cancer Treatment Market Growing at a CAGR of 8% from 2017 to 2025

Global Market Study on Bile Duct Cancer (Cholangiocarcinoma) Treatment: North America & Europe to Hold over ~30% Market Share During 2017-2025 Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Pfizer Company Life and Culture

You may also be interested in